INT311240

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 3.43
Pain Relevance 0.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (DPP4) extracellular region (DPP4) cell adhesion (DPP4)
Golgi apparatus (DPP4) endoplasmic reticulum (DPP4) plasma membrane (DPP4)
DPP4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 24 99.82 Very High Very High Very High
chemokine 3 72.00 Quite High
Neurotransmitter 2 29.68 Quite Low
antagonist 4 12.60 Low Low
Crohn's disease 2 11.32 Low Low
Piles 2 8.64 Low Low
agonist 29 5.00 Very Low Very Low Very Low
Neuropeptide 6 5.00 Very Low Very Low Very Low
headache 6 5.00 Very Low Very Low Very Low
substance P 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Colon Cancer 108 99.84 Very High Very High Very High
INFLAMMATION 16 99.82 Very High Very High Very High
Renal Cancer 39 98.84 Very High Very High Very High
Diabetes Mellitus 117 98.12 Very High Very High Very High
Hypoglycemia 25 97.48 Very High Very High Very High
Cancer 89 95.68 Very High Very High Very High
Inflammatory Bowel Disease 40 85.68 High High
Disease 15 85.68 High High
Hyperplasia 16 84.88 Quite High
Chronic Sinusitis 2 83.92 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, DPP IV relative expression (Figure 3A) decreased fortysixfold in chromophobe RCCs, whereas NEP mRNA levels (Figure 3B) decreased sixtysevenfold in the same tumor-type.
Negative_regulation (decreased) of Gene_expression (expression) of DPP IV associated with cancer and renal cancer
1) Confidence 0.59 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.67 Pain Relevance 0
The inverse relationship suggested that products of the inflammatory process inhibited DPP IV expression.
Negative_regulation (inhibited) of Gene_expression (expression) of DPP IV associated with inflammation
2) Confidence 0.55 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 0.43 Pain Relevance 0.13
Previous studies of our group detected that soluble serum CD26 (sCD26) levels were diminished in CRC patients as compared to healthy donors [15,16].
Negative_regulation (diminished) of Gene_expression (levels) of sCD26 associated with colon cancer
3) Confidence 0.37 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2912863 Disease Relevance 0.82 Pain Relevance 0
A positive sCD26 value was therefore ?
Negative_regulation (positive) of Gene_expression (value) of sCD26
4) Confidence 0.37 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2912863 Disease Relevance 0.99 Pain Relevance 0
ADA/EASD 2009 guidelines do not consider DPP-4 inhibitors as preferred (ie, tier 1 or tier 2) interventions because at the time of publication, DPP-4 inhibitors were considered too new and their long-term safety was still undetermined.12 However, these guidelines take note of the fact that DPP-4 inhibitors lower HbA1c levels by 0.6%–0.9%, are weight neutral, and are not associated with hypoglycemia when used as monotherapy.12

Emerging role of combination therapy

Negative_regulation (inhibitors) of Gene_expression (levels) of DPP-4 associated with hypoglycemia
5) Confidence 0.33 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.18 Pain Relevance 0
DPP-4 inhibitors: sitagliptin, vildagliptin and saxagliptin
Negative_regulation (inhibitors) of Gene_expression (saxagliptin) of DPP-4
6) Confidence 0.32 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.34 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox